An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,834 | -31,127 | -15,323 | -40,956 | -29,114 |
| Depreciation Amortization | -1,549 | -896 | -435 | -692 | -317 |
| Accounts payable and accrued liabilities | 2,660 | 1,009 | 1,423 | 2,497 | 1,816 |
| Other Working Capital | 5,957 | 3,552 | 2,075 | 3,718 | 631 |
| Other Operating Activity | 4,546 | 3,042 | 664 | 1,971 | 1,160 |
| Operating Cash Flow | $-36,220 | $-24,420 | $-11,596 | $-33,462 | $-25,824 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -112,348 | -27,136 | -14,013 | -93,836 | -76,391 |
| Sale Of Investment | 68,650 | 45,900 | 24,900 | 72,065 | 48,565 |
| Investing Cash Flow | $-43,698 | $18,764 | $10,887 | $-21,771 | $-27,826 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 85,315 | 19,249 | 199 | 70,366 | 70,366 |
| Common Stock Repurchased | N/A | N/A | N/A | -11 | -11 |
| Financing Cash Flow | $85,315 | $19,249 | $199 | $70,355 | $70,355 |
| Beginning Cash Position | 27,219 | 27,219 | 27,219 | 12,097 | 12,097 |
| End Cash Position | 32,616 | 40,812 | 26,709 | 27,219 | 28,802 |
| Net Cash Flow | $5,397 | $13,593 | $-510 | $15,122 | $16,705 |
| Free Cash Flow | |||||
| Operating Cash Flow | -36,220 | -24,420 | -11,596 | -33,462 | -25,824 |
| Free Cash Flow | -36,220 | -24,420 | -11,596 | -33,462 | -25,824 |